Reaction
Vitritis reporting signals
As of the last recalculation, Vitritis appears in 1,798 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is FARICIMAB (PRR 422.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Faricimab | 254 | 422.3 | 436.1 |
| Aflibercept | 456 | 226.3 | 229.7 |
| Ranibizumab | 138 | 65.1 | 65.4 |
| Prednisolone Acetate | 37 | 42.2 | 42.4 |
| Moxifloxacin Hydrochloride | 53 | 31.2 | 31.2 |
| Dorzolamide Hydrochloride And Timolol Maleate | 12 | 17.7 | 17.7 |
| Moxifloxacin | 20 | 16.6 | 16.6 |
| Atropine | 11 | 15.5 | 15.5 |
| Atropine Sulfate | 14 | 15.1 | 15.1 |
| Bevacizumab | 137 | 13.8 | 13.8 |
| Efavirenz | 13 | 13.6 | 13.6 |
| Posaconazole Delayed-Release | 9 | 9.5 | 9.5 |
| Ganciclovir Sodium | 8 | 8.8 | 8.8 |
| Timolol | 9 | 8.7 | 8.7 |
| Thiotepa | 7 | 8.5 | 8.5 |
| Lamivudine Oral | 18 | 8.3 | 8.3 |
| Tenofovir Disoproxil Fumarate Tablets | 6 | 8.1 | 8.1 |
| Lamivudine | 20 | 7.6 | 7.6 |
| Brimonidine Tartrate | 11 | 7.2 | 7.2 |
| Triamcinolone Acetonide | 19 | 7.2 | 7.2 |
| Tobramycin Solution | 7 | 6.8 | 6.8 |
| Tobramycin Sulfate | 7 | 6.6 | 6.6 |
| Posaconazole | 9 | 6.4 | 6.4 |
| Fludarabine Phosphate | 20 | 5.9 | 5.9 |
| Ranolazine | 5 | 5.6 | 5.6 |